“We are proud to advance into the next phase of our clinical journey for JANX007 and begin treating patients in our Phase 1b expansion studies,” said David Campbell, Ph.D., President and CEO of Janux. “We also look forward to our first R&D Day where we will unveil previously undisclosed preclinical programs that utilize our expertise and platform technologies to address significant unmet medical needs.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Buy Rating for Janux Therapeutics Inc. Driven by Strategic Advancements in Prostate Cancer Treatment with JANX007
- Buy Rating for Janux Therapeutics Inc: Promising PFS Data and Attractive Valuation
- Buy Rating for Janux Therapeutics Inc: Promising Clinical Trial Results and Positive Outlook for JANX007
- Janux Therapeutics initiates expansion studies in ENGAGER-PSMA-01 trial
- Buy Rating for Janux Therapeutics: Promising Technology and Strong Financial Position Amid Competitive Pressure